# Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

> **NCT00026182** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 99 (actual)

## Conditions studied

- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Nodal Marginal Zone B-cell Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Small Lymphocytic Lymphoma
- Splenic Marginal Zone Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab
- **BIOLOGICAL:** recombinant interleukin-12
- **OTHER:** laboratory biomarker analysis
- **OTHER:** questionnaire administration
- **PROCEDURE:** quality-of-life assessment

## Key facts

- **NCT ID:** NCT00026182
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-10
- **Primary completion:** 2005-02
- **Final completion:** —
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2013-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00026182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00026182, "Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00026182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*